Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market. A couple of months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback